Nuclear medicine and biology最新文献

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"154 ","pages":"Article 109603"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146661773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"154 ","pages":"Article 109604"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146661775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET imaging of [64Cu]copper(II) chloride and tetrathiomolybdate administration in animal models of triple-negative breast cancer","authors":"Michael R. Lewis ,&nbsp;Claudia G. Chambers ,&nbsp;Maryam Heidari-Kharaji ,&nbsp;Kanishka Sikligar ,&nbsp;Vivian A. Yang ,&nbsp;Alexander W. Schaedler ,&nbsp;Mojgan Golzy ,&nbsp;Lisa D. Watkinson ,&nbsp;Terry L. Carmack ,&nbsp;Joni M. Lunceford ,&nbsp;Colleen Garrett ,&nbsp;Christos Papageorgiou ,&nbsp;Jessica L. Talbott ,&nbsp;Charles A. Maitz ,&nbsp;Jeffrey N. Bryan ,&nbsp;Charles J. Smith","doi":"10.1016/j.nucmedbio.2025.109596","DOIUrl":"10.1016/j.nucmedbio.2025.109596","url":null,"abstract":"<div><h3>Background</h3><div>In the United States, breast cancer is the second leading cause of cancer-related death. Triple-negative breast cancer (TNBC) is of substantial concern, as it lacks the receptors usually targeted by conventional treatments. Triple-negative breast tumors have a high degree of copper metabolism for the synthesis of transporters, enzymes, and chaperones. Tetrathiomolybdate (TM) is a well-tolerated oral therapy that has been investigated for chelating copper from tumors in TNBC patients, resulting in extended remission. The overall goal of this research was to evaluate [⁶⁴Cu]CuCl₂ PET/CT imaging of copper utilization in this disease, in the presence and absence of TM.</div></div><div><h3>Methods</h3><div>Uptake, internalization, and efflux studies were performed in TNBC cells versus normal cells. Biodistribution experiments were then conducted in TNBC xenograft-bearing mice that were administered TM versus controls. PET/CT imaging of mice carrying TNBC tumors was also performed in the presence and absence of TM. Finally, imaging was performed in a healthy cat and in a cat with mammary carcinoma.</div></div><div><h3>Results</h3><div>SUM149 TNBC cells selectively took up, internalized, and retained [⁶⁴Cu]CuCl₂ more avidly than normal fibroblasts. When SUM149-bearing mice were given TM, tumor uptake decreased and tracer accumulation shifted predominantly to the liver and kidneys, compared to control mice, in which large quantities of ⁶⁴Cu were excreted into the intestines. These results were supported by PET/CT imaging of the mice. PET/CT of companion cats gave results similar to those obtained in mice, with high accumulation of radioactivity observed in the liver and gallbladder and moderate intestinal and renal clearance. In a cat with mammary carcinoma, tumor uptake of [⁶⁴Cu]CuCl₂ was highly conspicuous, even in close proximity to the liver.</div></div><div><h3>Conclusions</h3><div>Utilization of [⁶⁴Cu]CuCl₂ in triple-negative breast cancer can be detected efficiently in cell and animal models of this disease. The tracer was also used successfully to evaluate TM administration in the SUM149 TNBC mouse model. Furthermore, PET/CT imaging of both mice and cats with breast cancer shows the potential to monitor treatment with TM in a facile, noninvasive manner. We are currently conducting a clinical trial of [⁶⁴Cu]CuCl₂ PET/CT in companion cats with mammary carcinoma, with the future goal of evaluating the efficacy of TM in feline patients.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109596"},"PeriodicalIF":3.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scandium-47 as a radionuclide precursor: Feasibility of production in a 47Ca/47Sc generator-like system","authors":"Izabela Cieszykowska,&nbsp;Małgorzata Żółtowska,&nbsp;Dariusz Pawlak,&nbsp;Łukasz Sochaczewski,&nbsp;Zbigniew Tymiński,&nbsp;Justyna Marganiec-Gałązka,&nbsp;Renata Mikołajczak","doi":"10.1016/j.nucmedbio.2025.109595","DOIUrl":"10.1016/j.nucmedbio.2025.109595","url":null,"abstract":"<div><h3>Background</h3><div>Scandium-47 (⁴⁷Sc), a medium-energy β⁻ emitter with a half-life of 3.35 days and associated γ emission (159 keV, 68.1 %), is an attractive radionuclide for targeted radionuclide therapy and theranostics. Production of ⁴⁷Sc via neutron irradiation of enriched ⁴⁶Ca targets through the ⁴⁶Ca(n,γ)⁴⁷Ca → ⁴⁷Sc decay pathway offers advantages such as thermal neutron utilisation and minimised contaminant co-production. Efficient separation and repeated recovery of ⁴⁷Sc in a quasi-generator system are crucial for enabling its medical application.</div></div><div><h3>Results</h3><div>Neutron irradiations of calcium carbonate targets ⁴⁶Ca-enriched (5.2 % and 10.5 %) at the Maria research reactor yielded up to 5.18 GBq ⁴⁷Sc and 5.60 GBq ⁴⁷Ca at the end of bombardment. Separation of ⁴⁷Sc from ⁴⁷Ca was performed using DGA resin with recovery efficiencies of 81–97 % for ⁴⁷Sc and 98–99 % for ⁴⁷Ca in up to five consecutive elutions within 18 days. Radiochemical purity of eluted [⁴⁷Sc]ScCl₃ exceeded 95 % in initial separations. Radiolabelling studies with DOTA-TATE demonstrated effective molar activities up to 20 MBq/nmol and radiochemical purities &gt;98 %. Stability tests confirmed that the [⁴⁷Sc]ScCl₃ eluate remained suitable for radiolabelling for the entire testing period of up to 4 days post-elution. Trace metal analysis showed predominantly low contamination levels, with sporadic impurities attributed to handling conditions.</div></div><div><h3>Conclusions</h3><div>The ⁴⁷Ca/⁴⁷Sc quasi-generator system based on neutron irradiation of enriched ⁴⁶Ca targets offers a reliable source of high-quality ⁴⁷Sc for radiopharmaceutical applications. Multiple elutions from a single target enable sustained production of ⁴⁷Sc with excellent radionuclidic and radiochemical purity. These results support further development of ⁴⁷Sc as a theranostic radionuclide for larger-scale production. A preliminary specification for ⁴⁷Sc as a radionuclide precursor was proposed following the European Pharmacopoeia guidelines, providing a groundwork for future standardisation.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109595"},"PeriodicalIF":3.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matched pair suitability of 89Zr and 177Lu-labeled L804-LLP2A theranostics for targeting VLA-4 in melanoma","authors":"Cyril O.Y. Fong ,&nbsp;Ejike V. Iweha ,&nbsp;Fabio Gallazzi ,&nbsp;Anupam Mathur ,&nbsp;Olivia Heyne ,&nbsp;Jodi Mootz ,&nbsp;Madison Mayher ,&nbsp;David S. Tatum ,&nbsp;Darren Magda ,&nbsp;Carolyn J. Anderson","doi":"10.1016/j.nucmedbio.2025.109597","DOIUrl":"10.1016/j.nucmedbio.2025.109597","url":null,"abstract":"&lt;div&gt;&lt;div&gt;There is a need for chelators that are versatile for complexing multiple radiometals. We previously demonstrated that the macrocyclic 1,2-HOPO chelator, L804, has utility for complexing &lt;sup&gt;177&lt;/sup&gt;Lu(III) for radiopharmaceutical therapy and &lt;sup&gt;89&lt;/sup&gt;Zr(IV) for PET imaging with antibody-based agents. Here, we investigated whether &lt;sup&gt;89&lt;/sup&gt;Zr-radiolabelled peptidomimetic LLP2A could function as a diagnostic surrogate for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-LLP2A therapy in the targeting of VLA-4 overexpressed in melanoma, with and without an albumin-binding moiety (pIBA) for biological half-life extension.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;L804-LLP2A (&lt;strong&gt;1&lt;/strong&gt;) and L804-pIBA-LLP2A (&lt;strong&gt;2&lt;/strong&gt;) were synthesized and radiolabelled with &lt;sup&gt;89&lt;/sup&gt;Zr and &lt;sup&gt;177&lt;/sup&gt;Lu. Distribution coefficients, in vitro binding affinity, biodistribution, and PET/SPECT imaging data in the B16F10 tumor-bearing mice model of metastatic melanoma were collected.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Quantitative radiochemical yield (&gt;99 %) was achieved with &lt;sup&gt;89&lt;/sup&gt;Zr and &lt;sup&gt;177&lt;/sup&gt;Lu within 30 min at 25 °C. Through a shake flask method, the LogD&lt;sub&gt;7.4&lt;/sub&gt; distribution coefficients of [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;2&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;2&lt;/strong&gt; (−0.67 ± 0.06 and − 1.05 ± 0.10, respectively) indicated greater lipophilicity compared to their non-albumin binder containing analogues, [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; (−1.67 ± 0.19 and − 1.26 ± 0.12, respectively). The addition of pIBA to the tracer scaffold did not appreciably affect binding affinity of &lt;sup&gt;89&lt;/sup&gt;Zr- or &lt;sup&gt;177&lt;/sup&gt;Lu-labeled LLP2A to VLA-4, with the K&lt;sub&gt;d&lt;/sub&gt; values for [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; vs [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;2&lt;/strong&gt; (2.2 ± 0.2 vs 1.6 ± 0.2 nM) and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; vs [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;2&lt;/strong&gt; (8.4 ± 1.0 vs 10.8 ± 2.6 nM) being comparable. In B16F10 melanoma tumor-bearing mice, both [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; exhibited rapid blood clearance but had distinctly different biodistribution profiles. [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt; was retained more in the tumor, kidney, and spleen out to 48 h compared to [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt;. There was a rapid clearance from both tumor and normal tissues for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; out to 48 h, and aside from the muscle, tumor: non-tumor ratios were overall greater for [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;1&lt;/strong&gt; than those obtained for [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;1&lt;/strong&gt;. The albumin-binding [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-&lt;strong&gt;2&lt;/strong&gt; and [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-&lt;strong&gt;2&lt;/strong&gt; displayed more similar distribution profiles, with higher tumor and non-tumor tissue accumulation, and significantly slower blood clearance. Both tracers gradually cleared out of tumor and non-tumor tissues, although [&lt;sup&gt;","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109597"},"PeriodicalIF":3.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of glycoside-based nuclear medicine imaging agents for the sodium–glucose co-transporters in cancer cells","authors":"Kakeru Sato ,&nbsp;Ririka Handa ,&nbsp;Jianwei Yao ,&nbsp;Jinya Higashino ,&nbsp;Taiga Watanabe ,&nbsp;Ryotaro Abe ,&nbsp;Yuna Hamada ,&nbsp;Jundai Yamagata ,&nbsp;Yuma Momose ,&nbsp;Asuka Mizutani ,&nbsp;Masato Kobayashi ,&nbsp;Ryuichi Nishii ,&nbsp;Keiichi Kawai","doi":"10.1016/j.nucmedbio.2025.109591","DOIUrl":"10.1016/j.nucmedbio.2025.109591","url":null,"abstract":"<div><h3>Introduction</h3><div>Sodium–glucose co-transporters (SGLTs), particularly SGLT1 and SGLT2, play an active role in glucose uptake by cancer cells and have gained attention as novel therapeutic targets. However, the development of nuclear medicine imaging agents specific to SGLTs has not yet been explored. This study aimed to develop and evaluate radiolabeled glycoside derivatives targeting SGLT1 and SGLT2 for cancer imaging.</div></div><div><h3>Methods</h3><div>β-Arbutin, a structural analog of methyl-α-D-glucopyranoside (MDG) which is SGLTs substrate, and phlorizin, a SGLT2 inhibitor, were selected as glycoside compounds for radioiodination, [¹²⁵I]β-arbutin and [¹²⁵I]phlorizin were synthesized. The accumulation was measured in HEK293 cells transfected overexpress GLUT1, GLUT3, SGLT1, or SGLT2. Subsequent accumulation studies were conducted in LS180 and DLD-1 cancer cell lines, and the gene expression levels were quantified by real-time polymerase chain reaction (PCR). Biodistribution of both radiotracers was examined in tumor-bearing mice.</div></div><div><h3>Results</h3><div>[¹²⁵I]β-Arbutin had affinity for SGLT1 and SGLT2, whereas [¹²⁵I]phlorizin had affinity for SGLT1 and GLUT3. [¹²⁵I]β-Arbutin accumulated preferentially in SGLT1-high LS180 cells, whereas [¹²⁵I]phlorizin accumulated in GLUT3-high DLD-1 cells. <em>In vivo</em>, [¹²⁵I]β-arbutin exhibited favorable biodistribution with low brain and thyroid accumulation, rapid blood clearance, and high tumor-to-blood ratios in SGLT1-expressing tumors. Although [¹²⁵I]phlorizin also showed low brain and thyroid accumulation, its blood clearance was slower and tumor-to-blood ratios were lower.</div></div><div><h3>Conclusion</h3><div>[¹²⁵I]β-Arbutin is a promising radiopharmaceutical candidate for imaging cancers with high SGLTs expression.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109591"},"PeriodicalIF":3.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145691348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating [11C]methylreboxetine PET and MRI to map in vivo norepinephrine transporter distribution: A proof-of-concept study of noradrenergic vulnerability in neurodegeneration","authors":"Jaime D. Mondragon ,&nbsp;Sofia Marcolini ,&nbsp;Bruno Lima Giacobbo ,&nbsp;Philip H. Elsinga ,&nbsp;Rudi A.J.O. Dierckx ,&nbsp;Marleen Tollenaere ,&nbsp;Debby van Dam ,&nbsp;Peter P. De Deyn","doi":"10.1016/j.nucmedbio.2025.109581","DOIUrl":"10.1016/j.nucmedbio.2025.109581","url":null,"abstract":"<div><h3>Background</h3><div>The locus coeruleus (LC) and its noradrenergic projections are among the earliest sites displaying pathology in Alzheimer's disease (AD) and Parkinson's disease (PD). In vivo measures of norepinephrine transporter (NET) availability with [¹¹C]methylreboxetine ([¹¹C]MRB) positron emission tomography (PET) and structural magnetic resonance imaging (MRI) indices of LC integrity provide complementary, but rarely integrated biomarkers.</div></div><div><h3>Methods</h3><div>13 Healthy controls (HC), individuals with 12 AD or amnestic mild cognitive impairment due to AD (AD/aMCI), and 5 patients with PD underwent [¹¹C]MRB PET and high-resolution T1-weighted MRI. NET availability was quantified using [¹¹C]MRB PET SUV-ratio–based binding potential (SUVr-BP) in the LC and projection regions (hippocampus, amygdala, thalamus, and prefrontal cortex). LC structural integrity was indexed by LC MRI contrast-to-noise ratio (CNR), and projection region volumes were extracted with FreeSurfer. Group differences were assessed with Kruskal–Wallis tests, and PET–MRI associations were examined using Pearson correlations with Yeo–Johnson transformation to reduce outlier influence.</div></div><div><h3>Results</h3><div>No significant group-level differences in [¹¹C]MRB PET SUVr-BP or MRI measures were observed across HC, AD/aMCI, and PD. However, LC [¹¹C]MRB PET SUVr-BP correlated with LC MRI-CNR (<em>r</em> = 0.429, 95 % CI [0.082–0.684], <em>p</em> = 0.018). In contrast, PET–MRI associations in projection regions were weak and non-significant. Exploratory analyses confirmed expected differences in cognition, neuropsychiatric symptoms, and functional measures, most pronounced in AD/aMCI participants.</div></div><div><h3>Conclusions</h3><div>This proof-of-concept study demonstrates convergent multimodal assessment of LC integrity using [¹¹C]MRB PET and LC MRI-CNR, whereas projection regions showed divergent or absent associations. These findings highlight the potential of the LC as a target for multimodal biomarker development and support further investigation of these imaging strategies in larger, longitudinal cohorts to delineate their role in detecting noradrenergic vulnerability in neurodegeneration.</div></div><div><h3>Significance statement</h3><div>This study integrates [¹¹C]MRB PET and MRI to examine noradrenergic integrity in Alzheimer's and Parkinson's disease. Results demonstrate strong PET–MRI convergence in the locus coeruleus, but not in projection regions, highlighting the locus coeruleus as a sensitive biomarker target and supporting multimodal imaging approaches for early detection of neurodegenerative vulnerability.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109581"},"PeriodicalIF":3.0,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145622373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery of zinc-68 from gallium-68 cyclotron target effluent: A method to establish wet chemistry capabilities for metal precursor recovery in PET radiometals","authors":"Ian M. Horn ,&nbsp;Anna C. Bitzer ,&nbsp;Patrick L. Day ,&nbsp;Mark S. Jacobson ,&nbsp;Jeffrey M. McEarchern","doi":"10.1016/j.nucmedbio.2025.109582","DOIUrl":"10.1016/j.nucmedbio.2025.109582","url":null,"abstract":"<div><h3>Background</h3><div>Gallium-68 (68Ga) is a PET isotope that is finding more use in the clinical setting as a PET diagnostic tool, e.g. 68Ga PSMA is widely used in the diagnosis of prostate cancer, and 68Ga dotatate for the diagnosis of neuroendocrine tumors. Current production is mostly performed using either germanium-68/gallium-68 (68Ge/68Ga) generators or liquid targets containing zinc-68 (68Zn) and irradiated with protons in an accelerator. Recently, GE Healthcare published an article describing the production and purification of 68Ga using solid 68Zn target irradiation. The method described in this study to recover 68Zn from liquid target effluent may also be used to re-purify 68Zn from effluents from 68Ga production using solid targets. Preliminary studies, to be published in a follow-up paper, that result in electroplated solid 68Zn targets are briefly mentioned to demonstrate that such targets can be made from the 68Zn purified using this recovery method.</div></div><div><h3>Method</h3><div>An ion-exchange based method was used for purifying (or ‘recovering’) target material-containing effluent for future reuse in target preparation. This was accomplished using a column with Bio-Rad AG1-X8 resin bed of approximately 20–25 g of resin in a glass ion-exchange column. Eluted fractions from the ion-exchange column were tested using a NexION 350D ICP-MS to detect the presence of total zinc and trace contaminants Cu, Fe, Pb, Cr, Al, Mn, Ti, Ni, and Ag. The isotopic purity of the 68Zn in the effluent was also measured to confirm the original isotopic ratio.</div></div><div><h3>Results</h3><div>The results presented indicate that any contaminants in the effluent samples were reduced to levels below the limits of detection of analytical techniques commonly used in PET manufacturing laboratories (including ICP-OES).</div></div><div><h3>Conclusion</h3><div>This article provides a simple method for recovering 68Zn from liquid target effluent to be used in the plating of 68Zn targets for 68Ga solid target production. This method will allow academic/PET facilities to establish a wet chemistry process for recovering 68Zn and, using separation schemes published or developed elsewhere, and other precursors used for making solid cyclotron targets for isotope production.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"152 ","pages":"Article 109582"},"PeriodicalIF":3.0,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145578471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Ethyl- and Propylpinacol-Based Arylboronic Acid Esters as Stable Precursors for Copper-Mediated Radiohalogenation","authors":"Frederik Sachse,&nbsp;Markus Laube,&nbsp;Klaus Kopka,&nbsp;Sven Stadlbauer,&nbsp;Austin Craig","doi":"10.1016/j.nucmedbio.2025.109118","DOIUrl":"10.1016/j.nucmedbio.2025.109118","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"150 ","pages":"Article 109118"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145473329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical evaluation of two new neutrophil elastase inhibitors synthesized by palladium-mediated [11C]cyanations","authors":"Viola Wilson ,&nbsp;Hongchao Zhang ,&nbsp;Sergio Estrada ,&nbsp;Luke R. Odell ,&nbsp;Kim Lambrechts ,&nbsp;Olof Eriksson ,&nbsp;Gunnar Antoni","doi":"10.1016/j.nucmedbio.2025.109179","DOIUrl":"10.1016/j.nucmedbio.2025.109179","url":null,"abstract":"","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"150 ","pages":"Article 109179"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145473527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}